QUALITY OF LIFE AND TREATMENT ADHERENCE AMONG POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AT DUC GIANG GENERAL HOSPITAL IN 2025
Main Article Content
Abstract
Objective: To describe quality of life and treatment adherence among postmenopausal women with osteoporosis receiving outpatient treatment at Duc Giang General Hospital.
Subjects and methods: A cross-sectional descriptive study was conducted on 220 postmenopausal women with osteoporosis receiving outpatient treatment at Duc Giang General Hospital from August to December 2025. Osteoporosis was diagnosed according to World Health Organization standards. Quality of life was assessed using the SF-36 scale and treatment adherence was assessed using the GMAS scale.
Results: The overall quality of life score was 53.8 ± 11.6; physical quality of life score was 51.2 ± 13.1; mental quality of life score was 56.6 ± 12.4; 54.5% of patients had an average quality of life; 39.1% had a low quality of life. 55.5% of patients did not adhere to treatment, with an average GMAS score of 25.8 ± 4.6. The group with good treatment adherence had higher quality of life scores compared to the group with poor adherence (60.2 ± 9.8 vs. 48.8 ± 10.4; p < 0.001).
Conclusion: The quality of life of postmenopausal women with osteoporosis receiving outpatient treatment is moderate and is correlated with treatment adherence. Increased counseling and improved treatment adherence are needed to enhance patients’ quality of life.
Article Details
Keywords
Osteoporosis, quality of life, medication adherence.
References
[2] Papaioannou A, Kennedy C.C, Ioannidis G et al. The impact of osteoporosis and fragility fractures on health-related quality of life in postmenopausal women. Osteoporos Int, 2009, 20 (4): 551-562. doi: 10.1007/s00198-008-0702-1.
[3] Bastounis A, Ntzani E, Tzavara C et al. Comparing medication adherence in patients receiving bisphosphonates for preventing fragility fractures: a systematic review and network meta-analysis. Osteoporos Int, 2022, 33 (6): 1223-1233. doi: 10.1007/s00198-022-06350-w
[4] Fatoye F, Smith P, Gebrye T, Yeowell G. Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. BMJ Open, 2019, 9 (4): e027049. doi: 10.1136/bmjopen-2018-027049.
[5] Curtis J.R, Westfall A.O, Cheng H, Lyles K, Saag K.G, Delzell E. The relationship between bisphosphonate adherence and fracture risk: results from the fracture intervention trial. J Bone Miner Res, 2011, 26 (4): 683-689. doi: 10.1002/jbmr.274.
[6] Hiligsmann M, Cornelissen D, Vrijens B, Abrahamsen B, Al-Delaimy W.K, Biver E et al. Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an ESCEO working group. Osteoporos Int, 2019, 30 (1): 25-37. doi: 10.1007/s00198-019-05104-5.
[7] Yeam C.T, Chia S, Tan H.C.C, Kwan Y.H, Fong W, Seng J.J.B. A systematic review of factors affecting medication adherence among patients with osteoporosis. Osteoporos Int, 2018, 29 (12): 2623-2637. doi: 10.1007/s00198-018-4759-3.
[8] Hoang Duc Khanh, Doan Minh Chau, Mai Lan Dung, Ho Le Thuy Phuong, Ho Pham Thuc Lan. Burden of osteoporosis in Vietnam: an analysis of population risk. PLoS One, 2021, 16 (6): e0252592. doi: 10.1371/journal.pone.0252592.
[9] Watkins R.E, Plant A.J, Sang D, O’Rourke T, Gushulak B. Development of a Vietnamese version of the short form-36 health survey. Asia Pac J Public Health, 2000, 12 (2): 118-123. doi: 10.1177/101053950001200211
[10] Nguyen Huong Thao, Truong Hong Van, Vi Tuyet Mai, Taxis K, Nguyen Thang, Nguyen Trung Kien. Vietnamese version of the general medication adherence scale (GMAS): translation, adaptation, and validation. Healthcare (Basel), 2021, 9 (11): 1471. doi: 10.3390/healthcare9111471.
[11] Nguyễn Thị Thu Huyền, Đinh Mạnh Hải. Tuân thủ điều trị ở bệnh nhân loãng xương sau bơm xi măng đốt sống tại Bệnh viện Đại học Y Hà Nội. Tạp chí Nghiên cứu Y học, 2022, 154 (6): 44-51. doi: 10.52852/tcncyh.v154i6.782.